ANVS Annovis Bio, Inc.
Annovis Bio, Inc. (ANVS) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.30 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.1% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Annovis Bio, Inc.
Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.
Sector
Healthcare
Industry
Biotechnology